Loading...

SNSE SENSEI BIOTHERAPEUTICS INC US FDA Inspections 8-K Filing

SNS

SNS

SENSEI BIOTHERAPEUTICS INC

(SNSE)

2025 8-K

Show Summary

Show Summary

Reverse Stock Split

Financial Results

Clinical Trial Update

Stock Delisting Notice

Financial Results

Board Resignation

Management Change

Earnings Reports

Resignation of Director

Presentation Update

Clinical Data Presentation

Financial Results Announcement

Consulting Agreement with F...

Resignation of CFO

Stockholder Rights Agreemen...

Financial Results Announcement

Resignation and Appointment

Presentation Update

Financial Results Announcement

Rejection of Proposal

Clinical Data and Presentat...

Earnings Report

Investor Conferences

Amendment to Rights Agreement

Purchase Agreement for Stoc...

Earnings Reports

Presentation Update

Earnings Reports

Presentation Update

Nomination of Board Candidates

Stockholder Rights Plan

Bonuses paid in RSUs

External Links:

On March 27, 2025, Sensei Biotherapeutics, Inc. announced positive preliminary data for its drug Solnerstotug in treating resistant tumors and mentioned a conference call to discuss these results.

AI Assistant

SENSEI BIOTHERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.